Advances in Inflammatory Bowel Diseases (AIBD) 2020 Annual Conference

Treat IBD first in kids with COVID-19

Elvira Manzano, 20210129114000

Clinicians should first treat inflammatory bowel disease (IBD) in children with COVID-19, says an expert.

Subcutaneous vedolizumab maintenance attains clinical remission in ulcerative colitis

Elaine Soliven, 20210126000000

Patients with ulcerative colitis (UC) who received a subcutaneous (SC) formulation of vedolizumab as maintenance therapy achieved clinical remission at 52 weeks, according to the VISIBLE 1* trial presented at AIBD 2020.

Ozanimod aces in ulcerative colitis treatment

Pearl Toh, 20210121143000

The oral selective sphingosine-1-phosphate (S1P) receptor modulator ozanimod induced significant improvements in clinical remission and response, which were sustained up to 52 weeks, in patients with moderate-to-severe ulcerative colitis (UC), according to the phase III True North study presented at AIBD 2020 Congress.

What COVID-19 means for IBD care

Pearl Toh, 20210119150000

Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.

PPI use tied to less severe gum disease

Audrey Abella, 20210118100000

An inverse association was found between the use of proton pump inhibitors (PPIs) and the severity of periodontal disease (PD), according to data presented at AIBD 2020.

Cholecystectomy during intestinal resection not recommended for IBD patients

Audrey Abella, 20210114100000

Removal of the gallbladder (ie, cholecystectomy) is not recommended at the time of intestinal resection among individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2020.